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E-mail: hbjorns1@jhmi.eduKabuki syndrome (KS) is a rare causeof intellectual disability pri-
marily caused by loss-of-function mutations in lysine-specific
methyltransferase 2D (KMT2D), which normally adds methyl
marks to lysine 4 on histone 3. Previous studies have shown
that a mouse model of KS (Kmt2d+/bGeo) demonstrates disrup-
tion of adult neurogenesis and hippocampal memory. Proof-
of-principle studies have shown postnatal rescue of neurological
dysfunction following treatments that promote chromatin open-
ing; however, these strategies are non-specific and do not directly
address the primary defect of histone methylation. Since lysine-
specific demethylase 1A (LSD1/KDM1A) normally removes the
H3K4methyl marks added by KMT2D, we hypothesized that in-
hibition of KDM1A demethylase activity may ameliorate molec-
ular and phenotypic defects stemming fromKMT2D loss. To test
this hypothesis, we evaluated a recently developed KDM1A in-
hibitor (TAK-418) in Kmt2d+/bGeo mice. We found that orally
administered TAK-418 increases the numbers of newly born
doublecortin (DCX)+ cells and processes in the hippocampus in
a dose-dependent manner. We also observed TAK-418-depen-
dent rescue of histone modification defects in hippocampus
both by western blot and chromatin immunoprecipitation
sequencing (ChIP-seq). Treatment rescues gene expression
abnormalities including those of immediate early genes such
asFBJ osteosarcomaoncogene (Fos) andFBJosteosarcomaonco-
gene homolog B (Fosb). After 2 weeks of TAK-418, Kmt2d+/bGeo
mice demonstrated normalization of hippocampal memory de-
fects. In summary, our data suggest that KDM1A inhibition is
a plausible treatment strategy for KS and support the hypothesis
that the epigenetic dysregulation secondary to KMT2D dysfunc-
tion plays a major role in the postnatal neurological disease
phenotype in KS.
INTRODUCTION
Kabuki syndrome (KS) is a rareMendeliandisorder that affectsmultiple
systems, including neuro, immune, auditory, and cardiac systems.1 It isMolecular Therapy: Methods & C
This is an open access article under the CC BY-NC-characterized by distinctive facial features, growth retardation, andmild
to moderate intellectual disability.2 Human genetics studies have re-
vealed that this autosomal-dominant/X-linked condition is caused by
heterozygous/hemizygous loss of function in either of two genes with
complementary function, that is, KMT2D on human chromosome 12
or lysine-specific demethylase 6A (KDM6A) on human X chromo-
some.3,4 Both of these disease genes encode histone modifiers that
contribute to the opening of chromatin. Most (>70%) molecularly
confirmed cases of KS have loss-of-function variants in KMT2D.
KMT2D catalyzes the addition of methyl groups to lysine 4 of histone
3 (H3K4me1 and H3K4me3),5,6 which are marks associated with
open chromatin. KDM6A also participates in chromatin opening by
removing H3K27me3, a closed chromatin mark.7 It is therefore likely
that the observed gene dosage sensitivity in KS results from an imbal-
ance between open and closed chromatin states at or around critical
target genes. We hypothesize that it may be possible to restore this bal-
ance with drugs that promote open chromatin states.8
Our laboratory characterized a mouse model of KS1 (Kmt2d+/bGeo) and
found that these mice have many features that overlap with KS patient
phenotypes, including craniofacial abnormalities, growth retardation,
and immunedysregulation.9–11Thesemice alsodemonstrate anongoing
deficiency of adult neurogenesis in the subgranular zone (SGZ) of the
dentate gyrus (DG) in the hippocampus and hippocampal memory de-
fects. We have previously shown that these deficiencies improve after a
short-term (2–3 weeks) oral treatment with a histone deacetylase inhib-
itor (HDACi), AR-42.9Modulation of epigenetic modifications throughlinical Development Vol. 20 March 2021 ª 2021 The Author(s). 779
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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also rescue these same phenotypes.10 However, both of these strategies
are indirect, affecting chromatin opening throughmodulation of histone
acetylation rather thanhistonemethylation. Furthermore,HDACis have
been poorly tolerated in clinical trials,12 and a ketogenic diet is very strin-
gent and hard to implement in children who often have baseline feeding
problems and growth retardation, as is the case in KS. Recently, genetic
disruption of KDM1A, the factor that normally removes H3K4me1/2,
was shown to rescue disrupted chromatin states in KMT2D-deficient
embryonic stem cells.13 In this study, we used a specific inhibitor of
KDM1A activity, TAK-418, to demonstrate in vivo rescue of adult DG
neurogenesis, improvement of hippocampal memory deficits, chro-
matin remodeling, and gene expression abnormalities in Kmt2d+/bGeo
mice. TAK-418, also called 5-{(1R,2R)-2-[(cyclopropylmethyl)-amino]
cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide
monohydrochloride, was successfully advanced in preclinical develop-
ment and was recently given orphan designation by the EuropeanMed-
icinesAgency (EMA) and theUS Food andDrugAdministration (FDA)
for the treatment of KS. TAK-418 has already undergone phase 1 studies
on healthy volunteers to establish safety and tolerability (ClinicalTrials.-
gov: NTC03228433 and NCT03501069). Therefore, the TAK-418-
dependent rescue of disease phenotypes in Kmt2d+/bGeo mice provides
support for a possible therapeutic role in KS.
RESULTS
Kmt2d+/bGeo mice demonstrate a global decrease of histone
H3K4 methylation in the hippocampus
Kmt2d+/bGeomice contain an expression cassette encoding a b-galacto-
sidase neomycin resistance fusion protein (b-Geo) inserted into intron
50 of the Kmt2d gene locus on mouse chromosome 15. This cassette
contains a 50 end splice acceptor sequence and a 30 end cleavage andpol-
yadenylation signal. Themutated allele, therefore, results in a truncated
KMT2D protein with the peptide encoded by the first 50 exons of
KMT2D fused to b-Geo at the C terminus.9 The truncated KMT2D
fusion protein, therefore, lacks the C-terminal catalytic SET domain
ofKMT2D,which is responsible for itsH3K4methyltransferase activity.
Because KMT2D is a prominent mammalian H3K4 methyltransferase
and Kmt2d+/bGeo mice have disrupted hippocampal neurogenesis, we
hypothesized that we would see diminished levels of mono- and di-
methylated H3K4 (H3K4me1/2) in the granule cell layer of the DG in
Kmt2d+/bGeo mice. To test this, we performed western blots of histone
extracts from mouse hippocampi and observed significantly (p <
0.0001) reduced levels of H3K4me1 and H3K4me2 in Kmt2d+/bGeo
mice compared to Kmt2d+/+ littermates when normalized to total his-
tone 3 (H3) (Figures 1A and 1B; Figures S1A and S1B). Therefore,
although KMT2D and lysine methyltransferase 2C (KMT2C) have
some overlapping functions, our results indicate that the latter is unable
to compensate for the heterozygous loss of Kmt2d in the hippocampus.
Previously it has been reported that KMT2D is required for H3K4 tri-
methylation (H3K4me3) in bivalent promoters.6,14 Indeed, we found
that the level of H3K4me3 was also reduced (Figure 1C; Figure S1C),
and that the ratio of H3K4me3 to total histone 3 was significantly
reduced in Kmt2d+/bGeo mice compared to Kmt2d+/+ littermates780 Molecular Therapy: Methods & Clinical Development Vol. 20 March(p < 0.0016), although to a lesser extent than the observed deficiencies
of H3K4me1/2.
TAK-418 treatment rescues the deficiency of mono- and di-
methylated, but not tri-methylated, H3K4 in the hippocampus of
Kmt2d+/bGeo mice
TAK-418 is a selective inhibitor of the lysine-specific demethylase 1
(KDM1A/LSD1) recently developed by Takeda Pharmaceutical Com-
pany. KDM1A, in associationwith the corepressor of REST1 (CoREST)
complex, removesmethylation atH3K4me1/2 sites.15–18 Previously, ge-
netic disruption of KDM1A was found to rescue differentiation defects
in KMT2D-deficient embryonic stem cells.13 To test whether TAK-418
is able to functionallymodifyKDM1Aactivity and thereby rescue epige-
netic abnormalities in vivo in the hippocampus, mice were given TAK-
418 at 1 mg/kg/day by oral administration for 2 weeks and H3K4
methylation levels were characterized. Histones were then extracted
from dissected hippocampus for analysis. We observed significant
rescue (p<0.05) byTAK-418 treatment of thedeficientH3K4me1 levels
inKmt2d+/bGeomice compared toKmt2d+/+ littermates (Figure 1A; Fig-
ure S1A). Similarly, we observed a significant rescue (p < 0.05) of
H3K4me2 levels inKmt2d+/bGeomicewithTAK-418 compared to litter-
mates on vehicle (Figure 1B; Figure S1B). H3K4me3 levels were also
increased by TAK-418, albeit not to statistical significance (Figure 1C;
Figure S1C). Thus, in summary, we observed biochemical rescue of
H3K4 methylation in the hippocampus, a disease-relevant tissue,
althoughwe note that this was not a full rescue towild-type (WT) levels
in the treated Kmt2d+/bGeo mice (Figures 1A–1C). As expected, the ef-
fects of TAK-418 on all three H3K4 methylation marks were largely
correlated.We did not observe any changes in H3K4methylation levels
in the WT animals on TAK-418.
TAK-418 rescues defects of adult neurogenesis in Kmt2d+/bGeo
mice
Adult hippocampal neurogenesis is an ongoing process that persists
throughout life19,20 in which adult-born neural progenitors in the
SGZ give rise to excitatory granule cell neurons residing in the hippo-
campal DG.20 The neuroblast migration protein DCX is highly ex-
pressed in immature neurons and sharply decreases with maturation
of neurons,21,22 providing a cell stage/type-specific marker to quantify
adult neurogenesis in vivo. We tested the effects of TAK-418 on adult
neurogenesis as measured by DCX+ cells per mm2 in the DG and
SGZ. As before,9,10 we found decreased numbers of DCX+ cells in
Kmt2d+/bGeo mice compared to Kmt2d+/+ littermates. On TAK-418
treatment, this phenotype showed dose-dependent normalization
(Figure S2) with full rescue at the medium dose (1 mg/kg/day, Figures
1D and 1E). Dendrites can be visualized in some DCX+ cells, as DCX
is a cytoplasmic protein that is associated with microtubules present
in dendrites.23,24 We counted the DCX+ cells with dendrites and
found that Kmt2d+/bGeo mice have fewer DCX+ cells with dendrites
compared to Kmt2d+/+ littermates (Figure 1F), although this likely,
to some extent, reflects absolute cell numbers. Kmt2d+/bGeo mice
treated with TAK-418 have significantly increased numbers of
DCX+ cells with dendrites compared to Kmt2d+/bGeo mice treated


























































































































Figure 1. TAK-418 rescues histone H3K4 methylation abnormalities and neurogenesis defects in hippocampus of Kmt2d+/bGeo mice
(A–C) Quantification of H3K4me1, H3K4me2, and H3K4me3 levels from western blots of hippocampal lysates from both genotypes with and without 2 weeks of TAK-418
treatment. (D and E) A deficiency of DCX+ cells in the granule cell layer of the hippocampus seen in Kmt2d+/bGeo mice compared to littermates normalized after 2 weeks of
TAK-418. (F) A defect of the number of DCX+ processes is also rescued after 2 weeks on TAK-418. All sample values were normalized to the average of the untreated wild-
type animals. ANOVA: *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001.
www.moleculartherapy.orgalso appeared shorter than the dendrites in Kmt2d+/+ littermates,
which reached farther into the granule cell layer and even into the
molecular cell layer. TAK-418 treatment restored the dendrite length
and characteristics in Kmt2d+/bGeo mice, resulting in longer dendrites
extending throughout the granule cell layer and into the molecular
cell layer (Figure S3).MolecularTAK-418 treatment rescues the genome-wide deficiency of
H3K4 methylation in Kmt2d+/bGeo mice
Given the global H3K4methylation deficiency and rescue by TAK-418
in the hippocampus of Kmt2d+/bGeo mice, we next interrogated
the genome-wide histone profiles in hippocampus by chromatin
immunoprecipitation high-throughput sequencing (ChIP-seq). WeTherapy: Methods & Clinical Development Vol. 20 March 2021 781
Molecular Therapy: Methods & Clinical Developmentfirst performed H3K4me1-ChIP-seq on hippocampi harvested from
Kmt2d+/bGeo and Kmt2d+/+ mice treated with either vehicle or TAK-
418. Most H3K4me1 peaks (57.7%) appeared in intergenic regions,
which is consistent with known enhancer-associated roles of this
mark.5 A third of peaks (31.2%) appeared to be in introns, and fewer
were at the promoter/transcription start site (2.7%) or transcription
start site (1.8%). There was no obvious difference between the two
genotypes although there were a number of sites that significantly
changed in Kmt2d+/+ littermates with TAK-418 treatment (Fig-
ure S4A). In untreated hippocampi, we observed a total of 621 differ-
entially bound peaks of H3K4me1 in Kmt2d+/bGeo mice relative to
Kmt2d+/+ mice (Figure 2A; Table S1). Of these, 396 peaks were
decreased and 225 were increased in vehicle-treated Kmt2d+/bGeo
mice compared to Kmt2d+/+ littermates (Figure 2A). The 28 most sta-
tistically significant peaks are shown in Table S1. In general, Kmt2d+/+
mice had more differentially H3K4me1-bound peaks compared to
Kmt2d+/bGeo mice when either genotype was on vehicle (396/225,
1.76/1, Figure 2A). Upon treatment, we observed 622 differentially
bound H3K4me1 peaks, with 322 increased and 300 decreased in
Kmt2d+/bGeo on TAK-418 compared toKmt2d+/+mice on vehicle (Fig-
ure 2B; Table S2). The ratio of bound H3K4me1 in Kmt2d+/bGeo mice
on TAK-418 compared toKmt2d+/+mice on vehicle was 1 to 0.93 (Fig-
ure 2B). An inverse linear regression revealed a correlation coefficient
of 0.632 (Figure 2C) of log2 fold change of the common bound loci
between the comparison of Kmt2d+/bGeo/Kmt2d+/+ mice on vehicle
and Kmt2d+/bGeo on TAK-418/Kmt2d+/bGeo mice on vehicle. These re-
sults indicate that TAK-418 treatment leads to generalized, albeit par-
tial, rescue of the H3K4me1 deficiency.
We next performed H3K4me3 ChIP-seq. As expected, the most
H3K4me3 peaks are intragenic, with 18%–19% in the promoter re-
gion, 16%–17% peaks in exons, 33%–35% peaks in CpGs in in-
trons, and7% intergenic. There was no obvious difference in overall
distribution between the two genotypes, although again we did
observe a number of significant sites when comparing Kmt2d+/+ lit-
termates on and off TAK-418 (Figure S4B). We observed 262 loci
that were increased and 1,650 loci that were decreased in the
Kmt2d+/bGeo mice compared to the Kmt2d+/+ mice when vehicle
treated (Figure 2D; Table S3). On average, there is much more
H3K4me3 bound in the Kmt2d+/+ mice compared to Kmt2d+/bGeo
mice with a ratio of 6.63/1 (Figure 2D, both genotypes on vehicle).
In contrast, when we compared Kmt2d+/bGeo mice treated with
TAK-418 to Kmt2d+/+ mice treated with vehicle control, we observed
612 significantly increased loci and 1,972 significantly decreased loci
in Kmt2d+/bGeo mice compared to Kmt2d+/+ littermates. As before,
we observed more H3K4me3 binding upon treatment (3.22/1,
Kmt2d+/bGeo mice on TAK-418/Kmt2d+/+ mice on vehicle, Figure 2E;
Table S4). An inverse linear regression revealed a correlation coeffi-
cient (r) of 0.62636 upon plotting log2 fold change of the common
bound loci between the comparison of Kmt2d+/bGeo/Kmt2d+/+ mice
on vehicle and Kmt2d+/bGeoon TAK-418/vehicle mice on TAK-418,
suggesting that regions with low levels inKmt2d+/bGeomice on vehicle
increased with TAK-418 and vice versa, indicating a partial rescue of
the genome-wide deficiency of H3K4me3 by TAK-418 (Figure 2F).782 Molecular Therapy: Methods & Clinical Development Vol. 20 MarchGlobal gene expression changes are rescued in Kmt2d+/bGeo
mice on TAK-418
We next interrogated functional effects of the observed differential
histone modifications, as measured by changes in gene expression,
in order to define a list of potential KMT2D target genes in the hippo-
campus.We performed RNA sequencing (RNA-seq) on samples from
whole hippocampi harvested from Kmt2d+/bGeo mice and Kmt2d+/+
littermates treated with or without TAK-418. Differential gene expres-
sion analysis between Kmt2d+/bGeo mice and Kmt2d+/+ littermates
treated with vehicle control revealed a total of 136 differentially ex-
pressed genes (DEGs) (absolute log2 fold change >0.5, Figure 3A; Ta-
ble S5). Among the 136 DEGs, 74 genes were downregulated and 62
genes were upregulated in hippocampus from Kmt2d+/bGeo mice
compared toKmt2d+/+ littermates (Figure 3A).Genes thatwere down-
regulated inKmt2d+/bGeomice compared toKmt2d+/+ littermates were
enriched for networks of ionic transport and negative regulation of
synaptic signaling (Figure 3B). The pathways affected by genes upre-
gulated in Kmt2d+/bGeo mice compared to Kmt2d+/+ littermates
included tissue development, adhesion, and extracellular structure or-
ganization (Figure 3B). After treatment with TAK-418, however, we
observed a reversed pattern of expression effects. Among 130 DEGs,
only 38 genes were downregulated and 92 genes were upregulated in
Kmt2d+/bGeo mice on TAK-418 compared to Kmt2d+/+ littermates
treated with vehicle control (Figure 3D; Table S6). Pathways enriched
among genes upregulated in Kmt2d+/bGeomice treated with TAK-418
were involved in neurogenesis and neuronal projection development
(Figure 3E). The majority of DEGs (absolute log2 fold change <0.5)
in Kmt2d+/bGeomice compared to Kmt2d+/+ littermates were normal-
izedwithTAK-418 treatment (blue dots, Figure 3D). Among the genes
that were highly differentially expressed in untreated Kmt2d+/bGeo an-
imals and rescued with TAK-418 were the immediate early genes
(IEGs) Fos and Fosb, in addition to neurexophilin-3 (Nxph3),
relaxin/insulin-like family peptide receptor 1 (Rxfp1), downstream
targets of extracellular signal-regulated kinase (ERK) signaling, and ri-
bosomal protein genes (Figure 3C; Figure S5A). When we plotted the
log2 fold change of the common genes found in the comparison of
Kmt2d+/bGeo/Kmt2d+/+ mice on vehicle and Kmt2d+/bGeo mice on
TAK-418/Kmt2d+/bGeo mice on vehicle, we observed a highly signifi-
cant inverse correlation (R = 0.9), indicating that TAK-418 treat-
ment of Kmt2d+/bGeo mice rescued the disrupted expression levels of
genes in untreated Kmt2d+/bGeo mice (low genes became more highly
expressed and vice versa) to approximately what is normally seen in
Kmt2d+/+ littermates (Figure 3F). Finally, these three genes appeared
to show some favorable responses when H3K4me1 and H3K4me3
traces in treated animals were examined (Figures S5B and S5C).
The IEG Fos shows decreased expression in Kmt2d+/bGeo mice
that is rescued with TAK-418
Wevalidated gene expressionof some of themost interesting candidate
genes by qRT-PCR. NXPH3 is a specific ligand of synaptic alpha-neu-
rexins and is essential for efficient neurotransmitter release.25 Nxph3
expression is significantly downregulated (p < 0.009) in Kmt2d+/bGeo
mice compared to Kmt2d+/+ littermates (Figure 4A). Upon treatment
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Figure 2. Hippocampal genome-wide levels of H3K4me1 and H3K4me3 demonstrate TAK-418-dependent rescue
(A–C) Comparison of hippocampal H3K4me1 levels of Kmt2d+/bGeo mice on vehicle or TAK-418 compared to Kmt2d+/+ mice on vehicle. (D–F) Comparison of hippocampal
H3K4me3 levels of Kmt2d+/bGeo mice on vehicle or TAK-418 compared to Kmt2d+/+ mice on vehicle. Each point corresponds to a genomic location of a peak with a
statistically significant difference between the two genotypes. Log2 fold change >0.2 or <0.2 are in red, and others are in dark gray. To allow visualization of changes upon
TAK-418 treatment, the green dots indicate H3K4me1/3-bound locations that were significantly increased in Kmt2d+/bGeo mice on vehicle (B and E), and blue dots indicate
H3K4me1/3-bound peaks that were decreased in Kmt2d+/bGeo mice on vehicle (B and E).
www.moleculartherapy.orgFigure 4A). Fos and FosB are immediately early genes that respond to
extracellular stimuli. Fos, a marker of neuronal activity, has been asso-
ciated with a number of neural and behavioral responses to acute stim-
uli expression. Fos expression is downregulated in Kmt2d+/bGeo mice
(p < 0.05); however, upon treatment with TAK-418, the expression
level of Fos is upregulated significantly (p < 0.03) (Figure 4B). FosB
expression trends mirrored those of Fos, but to a lesser degree (Fig-
ure 4C). At the protein level, these gene expression abnormalities did
not appear to translate to significantly decreased levels in total hippo-Molecularcampus lysate fromKmt2d+/bGeomice compared with Kmt2d+/+ litter-
mate controls (Figures 4D and 4E).We hypothesize that the lack of dif-
ferences between the genotypes could be related to the differential cell
type composition in samples from brain tissue. In support of this hy-
pothesis, when we stained the mouse brain slices for FOS and counted
FOS+ cells and calculated the average number of FOS+ cells per mm2
from 9 to 10 slices per mouse with three to five mice in each examina-
tion group (Figure S6), we noticed significantly fewer FOS+ cells per
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Figure 3. TAK-418 rescues gene expression abnormalities in Kmt2d+/bGeo mice
(A and B) An overview of gene expression abnormalities (A, volcano plot) and a summary of major gene categories (B) among differentially expressed genes (DEGs) in
hippocampus when comparing Kmt2d+/bGeo and Kmt2d+/+ mice on vehicle. (C–E) Many of the DEGs from vehicle treatment (A) were normalized (D, blue dots) upon a
comparison of hippocampal gene expression levels between Kmt2d+/bGeo mice on TAK-418 and Kmt2d+/+ mice on vehicle. Red dots are DEGs with absolute log2 fold
changeR0.5 and p value <0.05. (C) A view of representative (top 10, all downregulated) DEGs betweenKmt2d+/bGeo and Kmt2d+/+mice on vehicle. (F) A correlation of DEGs
in Kmt2d+/bGeo (TAK-418/vehicle) and the two genotypes (Kmt2d+/bGeo/Kmt2d+/+ mice on vehicle) reveals TAK-418-dependent rescue.
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Molecular Therapy: Methods & Clinical Developmentcontrols (Figures 4F and4G).After 2weeks of treatmentwithTAK-418
in Kmt2d+/bGeo mice, the average FOS+ cells per mm2 increased,
although not to a significant level (Figures 4F and 4G; Figure S6). Fos
mediates a signaling cascade involving phosphorylation byERKs. Acti-
vated (phosphorylated) ERK (phospho-ERK) is known to be one of the
regulators of Fos expression and activity. The decrease in FosRNA and
protein levels inKmt2d+/bGeomice promptedus to look at the phospho-
ERK level in total hippocampal lysate. The ratio of phospho-ERK to to-
tal ERK was decreased significantly in Kmt2d+/bGeo mice compared
with Kmt2d+/+littermates (Figure S7), supporting the hypothesis that
the ERK-based activation of the Fos signaling cascade is disrupted in
Kmt2d+/bGeo mice.
TAK-418 rescues the visuospatial learning andmemory defect in
Kmt2d+/bGeo mice
Adult-born hippocampal neurons become integrated in the DG cir-
cuitry where they mediate neuronal plasticity in support of visuospa-
tial learning and pattern discrimination. Previously we have shown
that Kmt2d+/bGeo mice have defects in spatial learning and memory
formation as evaluated by a Morris water maze test.9 Herein, we
confirm9,10 that vehicle-treatedKmt2d+/bGeomice persistently crossed
the platform less frequently (p < 0.0007, Figure 5A) than did vehicle-
treated Kmt2d+/+ littermates in theMorris water maze. We also found
thatKmt2d+/bGeomice demonstrated a longer latency to reach the plat-
form (p < 0.0031, Figure 5B) and spend less time on the platform (Fig-
ure 5C) and in the quadrant with the platform (p < 0.0026, data not
shown) compared to Kmt2d+/+ littermates. The TAK-418 treatment
considerably ameliorated the defect observed in Kmt2d+/bGeo mice
in the Morris water maze test (Figure 5A). In the final probe trial,
the Kmt2d+/bGeo mice treated with TAK-418 had increased frequency
of crossing the platform compared to untreatedKmt2d+/bGeomice (p <
0.0206, Figure 5A). Similarly, Kmt2d+/bGeo mice treated with vehicle
consistently had increased latency to find the platform (p < 0.0088,
Figure 5B) and spent less time on the platform (p < 0.0131, Figure 5C),
both of which were rescued with TAK-418. There did not appear to be
any obvious confounders of either drug or genotype on vision ormus-
cle strength based on the results collected from theMorris watermaze.
Specifically, there were nomajor side effects onmuscles or vision after
treatment with TAK-418 for 2–3 weeks, as the average swimming
speed was very similar in both genotypes on and off TAK-418 (Fig-
ure 5D) and therewas nodifference in the 3-day visual trial with regard
to the latency to find the platform (Figure 5E). During the 5 days of
training, the mice improved over time, demonstrating appropriate
learning; however, the Kmt2d+/bGeo mice appeared to perform worse
(Figure S8) and were significantly worse on day 4 (p < 0.05) but ap-
peared to demonstrate some rescue on TAK-418, although it was
not significant (repeated-measures ANOVA).Figure 4. Gene expression abnormalities of disease-relevant candidate genes
immunofluorescence staining
Nxph3, fos, and fosb are disease-relevant DEGs and all demonstrate consistent decreas
gene expression change shows significant rescues with TAK-418. (D and E) Western blo
compared to littermates. (F and G) Immunofluorescence staining of tissue slices from Km
TAK-418 treatment. (F) is a representative immunofluorescence image of FOS from Km
786 Molecular Therapy: Methods & Clinical Development Vol. 20 MarchTAK-418 is well tolerated in mice at therapeutic levels and leads
to rescue of splenomegaly, another disease-relevant phenotype
We observed no obvious side effects in the mice that were on TAK-
418, including no effect on weight or general well-being (data not
shown). We have previously observed splenomegaly at or around
4months of age (data not shown). Given this finding, we kept a cohort
of mice on TAK-418 for 8 weeks (starting at 2 months of age) and
again observed no obvious side effect or impact on weight (no weight
loss or weight gain). We did, however, observe splenomegaly in the
Kmt2d+/bGeo mice treated with vehicle, but correction of the spleno-
megaly in Kmt2d+/bGeo mice on TAK-418 (Figure S9), indicating
that this phenotype may also be malleable by TAK-418 treatment.
DISCUSSION
Post-translationalmodifications of histoneproteins, such as acetylation,
methylation, phosphorylation, and ubiquitination, are thought to serve
as crucial regulatory signals to control gene expression in eukaryotic
cells and are important for maintaining genomic integrity.26 Emerging
evidence suggests that dysregulation of epigenetic modifications is
mechanistically linked to both cancer and developmental defects,
including neurodevelopmental disorders.27 Histone methylation, in
particular, confers active or repressive chromatin states in a locus-spe-
cificmanner. The histonemethylation state ismeticulously regulated by
the balance between two opposing enzyme systems: KMTs and lysine
demethylases (KDMs). Disease-causing variants in KMTs and KDMs
have been identified in multiple disorders in patients with intellectual
disability, indicating that altered regulation of histone methylation
can lead to intellectual disability.28 Pharmaceutical inhibition of epige-
netic targets counteracting the epigenetic effects of these loss-of-func-
tion variants has been investigated as a possible therapeutic option in
several epigenetic conditions, including KS.9,10,29
In recent years, data have emerged that support the notion that
KMT2D dysfunction affects cellular function in the hippocampus.
These include several studies that report more severe visuospatial
disruption (linked to hippocampus) in molecularly confirmed pa-
tients with KS compared to other individuals with non-KS intellectual
disability.30,31 MRI images also suggest a grossly smaller hippocam-
pus in individuals with molecularly confirmed KS.32 These studies
help set the stage for a potential clinical trial, as do recently developed
international diagnostic criteria for KS.2 These data also support the
strategy to focus on hippocampus and DG to estimate the effect of
treatment, although they in no way exclude that other brain regions
or cell types play a role in the neurological disease phenotype in KS.
Recently, genetic targeting of KDM1A was found to rescue a cellular
phenotype observed with loss of function of KMT2D in embryonicin Kmt2d+/bGeo mice are reflected in abnormal qRT-PCR, western blot, and
ed gene expression in Kmt2d+/bGeomice compared to littermates. (A–C) For fos, the
tting of FOS did not reveal a significant defect at the protein level in Kmt2d+/bGeomice
t2d+/bGeo mice and littermates demonstrates a significant defect that rescues upon



























































































































Figure 5. TAK-418 rescues the visual spatial learning and memory defect in Kmt2d+/bGeo mice
(A–C) Kmt2d+/bGeo mice have significant abnormalities in the number of times crossing the platform area during the probe trial (A), latency to find the platform (B), and time
spent on the platform (C); all defects are rescued on TAK-418. (D and E) These results are not confounded by muscle strength or vision, as Kmt2d+/bGeo mice have similar
average speed (D) and no significant defects in a visual flag-finding regimen compared to Kmt2d+/+ mice (E). ANOVA (A–D), repeated-measures ANOVA (E): *p < 0.05, **p <
0.01, ***p < 0.005.
www.moleculartherapy.orgstem cells.13 KDM1A, also known as LSD1 or AOF2, is the first identi-
fied FAD-dependent histone demethylase capable of specifically deme-
thylating mono- and di-methylated lysine 4 of histone H3 (H3K4me1
and H3K4me2), the very marks placed by KMT2D.15 This suggests
the feasibility of a more targeted therapeutic strategy for KS, namely
KDM1A inhibition. KDM1A associates with HDAC1/2, CoREST,
BHC80, andBRAF35.16 BRAF35,with itsHMGDNA-bindingdomain,
is thought to recruit the KDM1A/CoREST complex to the target sites.
Subsequent deacetylation of the histone tail by the HDAC1/2 at the
target sites then enables KDM1A to demethylate H3K4.17 It has been
demonstrated that hyperacetylated nucleosomes are less susceptible
to CoREST/LSD1-mediated demethylation,33 suggesting that hypoace-
tylated nucleosomes may be the preferred physiological substrates. We
have previously shown that AR-42, an HDACi, can rescue the learning
andmemory defect inKmt2d+/bGeomice9 after a short term (2–4weeks)
of treatment. However, AR-42, a pan-histone deacetylase inhibitor,
likely impacts deacetylase activities indiscriminately across a range of
distinct HDAC-containing multiprotein complexes. Such broadMolecularcellular effects may result in a narrow therapeutic window between dis-
ease efficacy and toxicity. Indeed, when we treated Kmt2d+/bGeo mice
with AR-42, we began to observe the effect at 5 mg/kg/day, with the
full effect obtained at 10 mg/kg/day. At 25 mg/kg/day, however, we
started to observe a cytotoxicity effect, reflected by fewer DCX+ cells
compared with Kmt2d+/bGeomice treated with vehicle.9 We had postu-
lated that the treatment effectwas likely indirect, primarily affecting his-
tone acetylation, with a secondary effect on histone methylation.9 An
alternative hypothesis is that AR-42 exerts its effect through inhibition
of HDAC1/2 activity in the KDM1A-CoREST complex, leading to hy-
peracetylation of the target sites, which are more resistant to KDM1A-
mediateddemethylation, thus retaining theH3K4methylation and thus
over time retaining more H3K4methylation. This may mean that low-
dose combined treatment with deacetylase inhibitor and demethylase
inhibitor or dual histone deacetylase and demethylase inhibitors target-
ing the CoREST complex may have synergistic effect and be a particu-
larly effective treatment for KS. In contrast to AR-42, TAK-418
achieved the full effect at 1 mg/kg/day with regard to DCX+ cells, andTherapy: Methods & Clinical Development Vol. 20 March 2021 787
Molecular Therapy: Methods & Clinical Developmentno adverse effects have been observed with a higher dose of TAK-418,
and H3K4 methylation levels did not change in WT animals on TAK-
418. This may suggest that Kmt2d+/bGeo mice may be more susceptible
to such changes than WT littermates and perhaps through ongoing
epigenetic compensation through the many layers of epigenetic modi-
fication.34Thus, our data suggest thatTAK-418, as a specific inhibitor to
KDM1A, may have the potential to be a single-agent treatment for KS
through its effects onH3K4methylation; however, it is noteworthy that
this phenotypic rescue occurred in the context of incomplete rescue of
H3K4methylation. This suggests that perhaps the histone methylation
needs to reach some threshold that lies under the normal levels ofH3K4
methylation.
In addition to the expected global increase of H3K4me1 and
H3K4me2 after treatment with TAK-418 in Kmt2d+/bGeo mice, we
also observed a global increase of H3K4me3, likely due to the accu-
mulation of H3K4me2 and subsequent conversion into H3K4me3
by H3K4 methyltransferases. Alternatively, the KDM1A complex
has been shown to be unstable while binding to methylated targets
sites. iBRAF, the paralog of BRAF35,35 may compete with BRAF35
for the same target sites and recruit the KMT2A complex, which sub-
sequently may enhance trimethylation of H3K4, however; this will
need to be explored in future studies. Although KDM1A-inhibiting
treatment is promising for KS, the dose will need to be optimized.
This is clear because missense mutations in KDM1A have been iden-
tified in three individuals with developmental delay,36–38 indicating
that too much KDM1A inhibition can be damaging. The develop-
mental symptoms in these individuals are similar to those of KS
(MIM: 147920), characterized by distinct craniofacial features,
including widely spaced teeth and palatal abnormalities, indicating
that too much disruption of KDM1A activity could also be detri-
mental to intellectual function. Although this protein also has non-
epigenetic function, it is likely that the cause of the phenotypes relates
to its epigenetic function because biochemical studies have demon-
strated that these mutant proteins exhibit reduced stability and deme-
thylase activity,38 indicating a loss-of-function mechanism.
OurRNAandChIP-seq data indicate that the IEGs such asFos andFosB
may be one class of genes that are affected in KS and show rescue on
TAK-418. Rusconi et al.39,40 have shown that the KDM1A complex in-
teracts with serum response factor (SRF) under resting conditions, and
an enrichment of the KDM1A complex with SRF has been detected in
the c-fos promoter, which contains the serum response element (SRE).
SRF is known to be constitutively bound to the DNA of its target genes,
and the interaction of the KDM1A complex with SRF modulates the
H3K4methylation level at the fos promoter.We also noted gene expres-
sion changes that would be consistent with decreased ERK signaling
and, in fact, ERK activation appears deficient in Kmt2d+/bGeo hippo-
campi compared to those in littermates. Previous data from fibroblasts
from KS individuals and zebrafish models of KS have implicated
decreased activation of this pathway,41,42 which is concordant with
our observations. Thus, both studies reveal abnormalities of ERK
signaling, and future studies should further elucidate whether ERK ab-
normalities play a mechanistic role in the pathogenesis of KS.788 Molecular Therapy: Methods & Clinical Development Vol. 20 MarchIn summary, in this study we show that oral administration of a
KDM1A specific inhibitor, TAK-418, can ameliorate neurological
problems at the cellular, molecular, gene expression, and functional
levels in a mouse model of KS (Kmt2d+/bGeo mice). TAK-418
treatment increases adult neurogenesis in adult mice, as indicated
by increased DCX+ cells in the granule cell layer of the hippocampus.
At the molecular level, TAK-418 increases the global level of mono-,
di-, and tri-methylated H3K4 (H3K4me1/2/3) inKmt2d+/bGeomice as
assessed by both western blot and ChIP-seq. TAK-418 treatment also
corrects the differential gene expression profile abnormalities found
in Kmt2d+/bGeo mice compared to Kmt2d+/+ littermates. Finally,
and most importantly, we show that TAK-418 can correct the func-
tional deficits by improving the learning and memory behavior of
Kmt2d+/bGeo mice. Currently, we do not know whether these effects
will translate in humans. However, the present data are informative
in respect to the TAK-418 dose range and exposure to be achieved
to produce pharmacologically relevant effects in Kmt2d+/bGeo mice.
In summary, our data support the hypothesis that KS is a treatable
cause of intellectual disability and that KDM1A inhibition may be a
novel and effective mechanism of action for the treatment of KS.MATERIALS AND METHODS
Animals
Ourmousemodel,Kmt2d+/bGeo, also namedMll2Gt(RRt024)Byg, was orig-
inally acquired from Bay Genomics (University of California) but back-
crossed in the Bjornsson laboratory. All experimental mice were on a
fully backcrossed C57BL/6J background (99% verified using a mouse
SNP chip). For treatment with TAK-418, mice were orally gavaged daily
with drug (TAK-418, Takeda) solubilized in vehicle (methylcellulose) or
with vehicle alone. Both drug and vehicle (methylcellulose)were shipped
from Takeda. Drug was administered for 14 days for adult neurogenesis
studies, after which mice were sacrificed on day 15. For behavioral
studies,Morris watermaze testing was initiated at day 15 after treatment
start at 8 weeks of age, and the drug was continued throughout the
behavioral studies (until at least day 23). A dose curve was initially per-
formed with three doses (0.5, 1, and 2 mg/kg/day). However, after that
initial study, all other experiments were done with a dose of 1 mg/kg/
day. For quantification of spleen size, evaluation was performed after
8 weeks of TAK-418 started at 8 weeks of age, since splenomegaly is
not observed until 12–16 weeks. For this reason, this cohort was kept
on TAK-418 for 8 weeks and to evaluate for side effects. Mouse
numbers for individual studies were as follows: ChIP-seq/RNA-seq, 3–
4 per group; immunohistofluorescence, 11–12 per group; qRT-PCR,
5–6 per group; and behavioral testing, 24–30 per group. Genotyping
was performed using the following primers: Mll2_exon50F (forward),
50-CTGTGTGGAACCGCATCATTG-30; Mll2_exon51R (reverse), 50-
CGGTTCTGATCTGGCACAGCC-30; and b-GeoR1, 50-CTCAGTG-
CAGTGCAGTCAGG-30. The Mll2_exon50F and Mll2_exon51R pair
amplifies sequences from the wild allele of KMT2D, and the Mll2_ex-
on50F and b-GeoR1 pair amplifies sequences specific for the targeted
allele. All experiments were performed usingmouse protocols approved
by the Animal Care and Use Committee of Johns Hopkins University
School of Medicine. The mouse protocols used for this study are2021
www.moleculartherapy.orgin accordance with the guidelines used by the National Institutes of
Health (NIH) for mouse care and handling.
Perfusion and cryosectioning
Mice were sacrificed with a lethal dose of xylazine/ketamine combina-
tion, after which they were transcardially flushed with PBS (1) with
heparin and then perfused with 4% paraformaldehyde (PFA)/PBS.
Brains were removed from the skulls and cryopreserved in 30% su-
crose 0.1 M phosphate solution overnight at 4C. Brains were frozen
and sectioned using a Microm HM550 cryostat (Thermo Scientific).
Sectioning was performed at 30-mm intervals, and every section of
the brain was collected onto the slide in a series of six slides with
12 slices on each slide and stored in a 80C freezer prior to use.
Immunofluorescence staining
Pre-mounted slides were thawed and washed once in Tris-buffered
saline (TBS) (1). Slices were briefly permeabilized in TBS (1)
with 0.4% Triton X-100 (30 min), followed by blocking with TBS
with 3% donkey serum and 0.05% Triton X-100 for 1 h at room tem-
perature. Next, each slide was incubated with primary antibody (in
TBS with 3% donkey serum and 0.05% Triton X-100) overnight
(O/N) at 4C. After three to five washes in TBS with 0.05% Triton
X-100, Alexa Fluor-conjugated secondary antibodies with DAPI
counterstain were added to the slide for 1 h at room temperature.
Slides were mounted with ProLong antifade (Thermo Fisher Scienti-
fic, catalog #P36930) after several washes in TBS with 0.05%Triton X-
100 and a final wash of TBS. Images were taken with an LSM 780
confocal microscope. Antibodies used included anti-DCX (Santa
Cruz, catalog #sc-8066) and anti-c-fos (Abcam, catalog #190289).
Granule cell layer and quantification of DCX+ cells
The area of the granule cell layer and DCX+ cells was measured using
ImageJ as previously described.9 Briefly, we traced the granule cell
layer by hand and counted DCX+ cells within this area in all slides.
We performed an independent count of all DCX+ processes. Count-
ing was performed by an investigator who was blinded to genotype
and/or drug exposure.
Western blotting
Hippocampuswasdissected, snap-frozen, andkept at80C.Histones
were extracted following a published acid extraction protocol.43 Briefly,
250 mL of TED buffer (0.5% Triton X-100, 2 mM PMSF, and 0.02%
NaN3 in PBS) was added and hippocampal tissue was disaggregated
by 50–60 strokes with a pellet pestle. Nuclear pellets were collected at
10,000 rpm for 1 min at 4C and resuspended in 50 mL of acid extrac-
tion buffer (0.5 N HCl in 10% glycerol). After O/N incubation in acid
extraction buffer, the supernatant was collected and histones were
precipitated with acetone O/N at 20C. Histone pellets were subse-
quently dissolved in water. For whole-cell lysate, we disaggregated hip-
pocampal tissue in radioimmunoprecipitation assay (RIPA) buffer
(150 mM NaCl, 1.0% Nonidet P-40 [NP-40], 0.5% sodium deoxycho-
late, 0.1% SDS, 50 mM Tris [pH 8.0]) by 50–60 strokes with a pellet
pestle. After incubation for 2 h at 4C, supernatant was collected.
Amount of protein was quantified using a BSA protein assay. ProteinsMolecularwere fractionated in 4%–12% NuPAGE Bis-Tris gel. Antibodies used
included the following: anti-histone H3 (Cell Signaling Technology,
catalog #3638), anti-H3K4me3 (Cell Signaling Technology, catalog #
9727), anti-H3K4me2 (Cell Signaling Technology, catalog #9725),
anti-H3K4me1(Abcam, catalog #ab8895), anti-c-fos (Abcam, catalog
#190289), anti-phospho-p44/42 mitogen-activated protein kinase
(MAPK) (Erk1/2) (Cell Signaling Technology, catalog #9106), anti-
p44/42 MAPK (Erk1/2) (Cell Signaling Technology, catalog #9102),
anti-b-actin (Cell Signaling Technology, catalog#3700).
Behavioral testing
No exclusion criteria were used other than decreased visual acuity as
evaluated by visible platform training (see below). The investigator
was blinded to genotype and drug exposure status during testing.
ForMorris water maze testing, mice were placed in a 1.1-m diameter
tank filled with room temperature water dyed with nontoxic white
paint. For analytical purposes, the tank was divided into four quad-
rants, with one quadrant containing a small platform submerged
1.5 cm beneath the water. On each day of training, mice were placed
in the tank in a random quadrant facing away from the center and
allowed to swim until they found the platform. Once they reached
the platform, they were left there for 30 s. If they did not reach
the platform after 60 s, they were placed on it for 30 s. Each mouse
was given four trials per day (for 5 days) with an inter-trial interval
of 5–20 min and subsequently returned to its home cage. Latency to
reach the platform was measured during each trial. The day after the
final day of training, the platform was removed for a probe trial
where mice were placed in the tank for 90 s. The average number
of crossings of the platform’s previous location was recorded.
Visible/flagged platform training was also performed for 3 days right
before the hidden platform to ensure no problems with sight.
During visible training, a visible flag was placed on the submerged
platform, and the time for each mouse to reach the platform was
measured during each 60-s trial, four of which were run in the
same way as the hidden platform training. For all training and probe
testing, data were recorded both manually and electronically with
ANY-maze software (San Diego Instruments) when applicable. Dif-
ferences in the number of platform crossings as well as the latency of
the first crossing of the platform during the probe trial were
compared between groups with an ANOVA with the significance
value set at p < 0.05.
RNA-Seq/ChIP-Seq
For RNA-Seq and ChIP-Seq, 2-week-old mice were given TAK-418 at
a dose of 1 mg/kg body weight for a period of 2 weeks. Hippocampi
were harvested at the end of the 2-week treatment. RNAwas extracted
with a Direct-zol RNAmicroprep kit (Zymo Research), and RNA-seq
libraries were constructed with an NEBNext Ultra RNA library prep
kit for Illumina. Pooled RNA libraries were sequenced on a HiSeq
2500 using 150-bp paired-end sequencing. For ChIP-seq library con-
struction, nuclear lysate preparation and ChIP followed the ENCODE
protocol from the Bing Ren laboratory with chip graded anti-
H3K4me3 (Abcam, catalog #ab8580) and anti-H3K4me1 (Abcam,
catalog #ab8895). After reverse cross-linking and purifying the DNATherapy: Methods & Clinical Development Vol. 20 March 2021 789
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tra II DNA library prep kit for Illumina based on the manufacturer’s
recommendations. Pooled ChIP DNA libraries were sequenced on a
HiSeq 2500 using a flow cell for 150-bp paired-end size.RNA-Seq/ChIP-Seq analysis
RNA-Seq
Transcriptomic data collected by RNA-seq were analyzed to deter-
mine the genes that were present in each sample and condition, their
expression levels, and the differences between expression levels
among different experimental conditions. Following quality checking
with the software FastQC, reads were mapped to the mouse genome
version mm10 with the alignment tool TopHat2 v2.1.0,44 which al-
lows for large “gaps” in the alignment, representing introns. The
aligned reads were assembled with CLASS2 v2.1.745 to create partial
genes and transcript models (transfrags). Transfrags from all samples
were further merged with cuffmerge and mapped to the GENCODE
M17 gene models46 to create a unified set of gene annotations for dif-
ferential analyses. Lastly, gene (transcript) expression levels were
computed, and DEGs (transcripts) were determined separately with
the tools Cuffdiff2 v2.2.147 and DESeq.48 DEGs were further analyzed
and graphed with R, a public free resource for statistical computing
and graphing.
ChIP-Seq
The reads collected by H3K4me1 and H3K4me3 ChIP sequencing
were first trimmed 5 bp at 50 end with the software seqtk (https://
github.com/lh3/seqtk), followed by mapping with the short sequence
alignment tool Bowtie 2.49 The aligned sequences were indexed with
software SAMtools for easy viewing in IGV (Integrated Genome
Viewer). The THOR software50 was then used to detect and analyze
differential peaks in two sets of ChIP-seq data from distinct biological
conditions with replicates. HOMER51 and Gene Ontology (GO) anal-
ysis (http://geneontology.org/) was used to annotate the peaks, and
custom scripts were written to filter THOR output, gather statistics,
and reformat files. Differential peaks were further analyzed and
graphed with R. All data have been posted to GEO (GEO:
GSE146727, GSE146728, and GSE146729).SUPPLEMENTAL INFORMATION
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